First American Bank Takes $1.65 Million Position in The Cooper Companies, Inc. $COO

First American Bank purchased a new position in The Cooper Companies, Inc. (NASDAQ:COO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,011 shares of the medical device company’s stock, valued at approximately $1,646,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COO. J.Safra Asset Management Corp grew its stake in Cooper Companies by 204.8% in the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after acquiring an additional 340 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in shares of Cooper Companies in the second quarter valued at approximately $36,000. MUFG Securities EMEA plc purchased a new stake in shares of Cooper Companies in the second quarter valued at approximately $42,000. Assetmark Inc. grew its stake in Cooper Companies by 357.8% in the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock worth $44,000 after purchasing an additional 483 shares in the last quarter. Finally, Allworth Financial LP increased its holdings in Cooper Companies by 36.6% during the 2nd quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock worth $68,000 after purchasing an additional 257 shares during the period. Institutional investors own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

COO has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 target price (up from $94.00) on shares of Cooper Companies in a research report on Friday, December 5th. Barclays restated an “overweight” rating and issued a $91.00 price objective on shares of Cooper Companies in a report on Monday, December 8th. The Goldman Sachs Group reiterated a “sell” rating and set a $71.00 target price (up from $64.00) on shares of Cooper Companies in a report on Monday, December 8th. JPMorgan Chase & Co. upped their price target on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, December 5th. Finally, KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and an average price target of $90.15.

Cooper Companies Stock Performance

COO stock opened at $82.20 on Tuesday. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $100.24. The firm has a market cap of $16.11 billion, a price-to-earnings ratio of 43.72, a PEG ratio of 2.36 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The firm has a 50-day simple moving average of $76.07 and a two-hundred day simple moving average of $72.53.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the firm earned $1.04 EPS. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a stock buyback plan on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Cynthia L. Lucchese bought 1,784 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average cost of $84.06 per share, for a total transaction of $149,963.04. Following the purchase, the director directly owned 9,445 shares in the company, valued at $793,946.70. This represents a 23.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Holly R. Sheffield purchased 1,230 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was acquired at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the purchase, the insider owned 39,052 shares of the company’s stock, valued at $3,153,449. The trade was a 3.25% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 16,014 shares of company stock valued at $1,304,416. Corporate insiders own 1.98% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.